Related Experiment Video
Updated: Jul 4, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Pricing and reimbursement of pharmaceuticals in Italy
Pietro Folino-Gallo1, Simona Montilla, Mario Bruzzone
1Centre for Studies, Italian Medicines Agency (AIFA), Rome, Italy. p.folino@aifa.gov.it
Abstract:
In Italy the price setting of medicines reimbursed by the National Health Service is regulated at the central level by AIFA, the national regulatory authority. Prices of non reimbursed medicines are indeed freely established, with some limitations, by pharmaceutical companies. To contain pharmaceutical expenditure and rationalise the whole sector the following measures have been introduced in the past years: a threshold to public pharmaceutical expenditure (PPE); a reference price system (RPS) for off-patent medicines; a pay-back mechanism as an alternative to price cut. In 2008 Italy launched a reform of the pharmaceutical expenditure governance system with the aim to introduce stability and promote development and competitiveness in the pharmaceutical sector.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Equivalents
Dosage Regimen: Individualization
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Control Governance: Regulatory Bodies and Their Impact

